Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Advair Competition: Teva’s AirDuo Approved But Not Therapeutically Equivalent

Jan 31 2017

• By Sue Sutter

Related Content

Just A Product, Not A Pathway, FDA Says Of Omnitrope Approval

May 31 2006

Teva Advancing Two Advair Generics With Late 2017 Target

Aug 04 2016

Advair: A Big Generic Opportunity And A Big Question Mark In 2017

Dec 29 2016

Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain

Sep 03 2012

Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair

Jan 30 2017

Advair Generics Likely Lucrative Product For Few That Can Clear High Bar

Sep 16 2013

Teva Changes Its Tune On Substitutable Generic Advair

Oct 08 2013

Related Companies

Teva Pharmaceutical Industries Ltd.

GSK plc

Viatris Inc.

Hikma Pharmaceuticals plc

Novartis AG

Novartis AG

Allergan plc

Pfizer Inc.

Amgen, Inc.

Additional Topics

United States Approvals Regulation Review Pathway BioPharmaceutical Respiratory

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window